Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

Drugmakers hike prices 350 drugs in January, including Pfizer's COVID-19 vaccine and hospital drugs, with a median increase of 4%.

Reporting from Washington — Pharmaceutical giant Pfizer Inc. is paying $14 billion to buy Medivation Inc., a San Francisco biotech company that sells a high-priced prostate cancer medication ...